Chimerix INC Form 4 insider transactions

Director Victoria Vakiener reports the disposal of Chimerix stock options following the company's merger with Jazz Pharmaceuticals on April 21, 2025.

Following the merger of Chimerix with Jazz Pharmaceuticals, CEO Michael Sherman reports the disposal of common stock and cancellation of stock options.

Thomas Riga, COO and CCO of Chimerix, reports the disposal of common stock and stock options following the merger with Jazz Pharmaceuticals, as per the terms of the merger agreement.

Director Pratik S. Multani reports the disposal of employee stock options in Chimerix following the company's merger with Jazz Pharmaceuticals, where Chimerix became a wholly-owned subsidiary.

Director Fred A. Middleton reports the disposal of Chimerix shares and options due to the merger with Jazz Pharmaceuticals, where shares were acquired for $8.55 each.

Robert J. Meyer, a director of Chimerix, reported the disposal of common stock and stock options due to the merger with Jazz Pharmaceuticals, where Chimerix became a wholly-owned subsidiary.

Allen S. Melemed, Chief Medical Officer of Chimerix, reports the disposition of shares and stock options following the company's merger with Jazz Pharmaceuticals.

Michelle LaSpaluto, CFO of Chimerix, reports the disposal of shares and cancellation of stock options following the company's merger with Jazz Pharmaceuticals on April 21, 2025.

Director Marc Kozin reports the disposal of Chimerix stock options following the merger with Jazz Pharmaceuticals, where options were converted to cash payments.

David Jakeman, VP of Finance and Accounting at Chimerix, reports the disposal of shares and cancellation of stock options following the merger with Jazz Pharmaceuticals.

Following the merger of Chimerix with Jazz Pharmaceuticals, director Martha J. Demski reported the disposal of common stock and stock options as per the merger agreement.

Lisa Decker, a director at Chimerix, disposed of employee stock options as part of the merger agreement with Jazz Pharmaceuticals, receiving cash payment for 'in the money' options.

Michael Andriole, President and CEO of Chimerix, reports the disposal of common stock and stock options due to the merger with Jazz Pharmaceuticals, where Chimerix became a wholly-owned subsidiary.

Michael Alrutz, SVP and General Counsel of Chimerix, reports the cancellation of shares and stock options following the merger with Jazz Pharmaceuticals, as detailed in a Form 4 filing.

Allen S. Melemed, Chief Medical Officer of Chimerix, Inc., sold 3,065 shares of common stock to cover tax liabilities incurred upon the vesting of restricted stock units.

Chimerix CEO Michael Andriole sold 7,370 shares of common stock on February 13, 2025, to cover tax liabilities incurred from vesting of restricted stock units.

Michael Alrutz, SVP and General Counsel of Chimerix, Inc., sold 1,600 shares of common stock to cover tax liabilities related to a restricted stock unit award.

David Jakeman, VP of Finance and Accounting at Chimerix, sold 300 shares of common stock to cover tax liabilities related to a restricted stock unit award.

Michelle LaSpaluto, CFO of Chimerix, Inc., sold 2,260 shares of common stock on February 13, 2025, to cover tax liabilities incurred from vesting of restricted stock units.

David Jakeman, VP of Finance and Accounting at Chimerix, sold 2,800 shares of common stock to cover tax liabilities from vested restricted stock units.

Michelle LaSpaluto, CFO of Chimerix, Inc., sold 1,015 shares of common stock on January 30, 2025, to cover tax liabilities incurred from vesting restricted stock units.

Chimerix CEO Michael Andriole sold 2,350 shares of common stock on January 30, 2025, to cover tax liabilities incurred from vesting restricted stock units.

Chimerix's Chief Financial Officer, Michelle LaSpaluto, acquired shares and stock options, and also reported existing holdings, as part of a recent filing.

Chimerix's Chief Medical Officer, Allen S. Melemed, reported the acquisition of common stock and stock options, as well as the disposal of some shares.

David Jakeman, VP of Finance and Accounting at Chimerix Inc., reported the acquisition of 10,855 shares of common stock and 65,000 stock options.

Thomas J. Riga, COO and CCO of Chimerix, Inc., reports the acquisition of common stock and stock options, as well as the vesting of restricted stock units.

Chimerix SVP and General Counsel Michael Alrutz received stock awards and stock options, increasing his holdings in the company.

Chimerix CEO Michael Andriole acquired 150,000 shares and 900,000 stock options, according to a recent SEC Form 4 filing.

Director Fred A. Middleton reports a transfer of 60,000 Chimerix shares to an irrevocable trust for no consideration, while also disclosing beneficial ownership through various Sanderling Venture Partners entities.

Chimerix CEO Michael Andriole sold 1,285 shares of common stock on August 8, 2024, to cover tax liabilities incurred from vesting restricted stock units.